Mentice AB (STO: MNTC) completes the acquisition of ANKYRAS

GOTHENBURG, Sweden, July 1, 2022 /PRNewswire/ — Mentice AB (STO: MNTC) (“Mentice”) Mentice today confirms the acquisition of the Ankyras business from Galgo Medical SL, as previously communicated via the press release on 9th June 2022, now has been completed.

The information was submitted for release, through the request of the contact person below, at 21:20 CEST on 30 June 2022.

For more information, please contact:

Göran Malmberg, CEO

Telefon: +46 70309 22 22


About Mentice

Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at:


This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 30th of June 21.20 CET, 2022.  

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

This information was brought to you by Cision–sto–mntc–completes-the-acquisition-of-ankyras,c3594715

The following files are available for download:




Source link

The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy